Marcela V. Maus, M.D.,Ph.D.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Marcela V. Maus, M.D.,Ph.D. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Marcela V. Maus, M.D.,Ph.D.: 8 sponsored US clinical trials, 6 recruiting.
Marcela V. Maus, M.D.,Ph.D. sponsors 8 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is High Grade B-Cell Lymphoma, with 2 trials.
Upper-quartile sponsor footprint
Marcela V. Maus, M.D.,Ph.D. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
NCT07388277
Emapalumab Prevention of CAR-T Cell Associated Toxicities
NCT06550141
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
NCT06026319
Long-term Follow-up of Subjects Treated With CAR T Cells
NCT05024175
CARv3-TEAM-E T Cells in Glioblastoma
NCT05660369
TriPRIL CAR T Cells in Multiple Myeloma
NCT05020444
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
NCT04150913
CAR-37 T Cells in Hematologic Malignancies
NCT04136275
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
What is open in the Marcela V. Maus, M.D.,Ph.D. pipeline
6 recruiting of 8 indexed (75% open); 2 completed (25%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: High Grade B-Cell Lymphoma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Marcela V. Maus, M.D.,Ph.D.: open-pipeline peers nationwide
Peers matched on 8 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Marcela V. Maus, M.D.,Ph.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 75% open enrollment (± trial volume)
- A2 Biotherapeutics · 75% recruiting · 4 trials
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
Related
What to do with this Marcela V. Maus, M.D.,Ph.D. page
8 registered trials is a research-attention snapshot, not an endorsement of Marcela V. Maus, M.D.,Ph.D. or any single study.
- 6 of Marcela V. Maus, M.D.,Ph.D.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- High Grade B-Cell Lymphoma is the condition Marcela V. Maus, M.D.,Ph.D. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See High Grade B-Cell Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Marcela V. Maus, M.D.,Ph.D. pipeline card: 8 registered trials from official public datasets.Report a data error.